Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas

@article{Kato2014SpecificMA,
  title={Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas},
  author={Yukinari Kato},
  journal={Brain Tumor Pathology},
  year={2014},
  volume={32},
  pages={3-11}
}
Mutations of isocitrate dehydrogenase 1/2 (IDH1/2) have been reported in gliomas and other types of tumors, such as acute myeloid leukemias, cartilaginous tumors, intrahepatic cholangiocarcinomas, osteosarcomas, and giant cell tumors of bone. In gliomas, IDH mutations uniformly occur in the functionally critical arginine 132 residue (R132) of IDH1 and arginine 172 residue (R172) of IDH2. IDH1 and IDH2 catalyze the oxidative carboxylation of isocitrate to α-ketoglutarate (α-KG) in the cytosol… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes

Veterinary Research Communications • 2017
View 4 Excerpts
Highly Influenced

Pathology of oligodendroglia: An overview.

Neuropathology : official journal of the Japanese Society of Neuropathology • 2017

References

Publications referenced by this paper.
Showing 1-10 of 83 references

Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations

M Kato Kaneko, S Ogasawara, Y Kato
Tohoku J Exp Med • 2013
View 8 Excerpts
Highly Influenced

IDH1/2 mutation detection in gliomas

Brain Tumor Pathology • 2014
View 2 Excerpts

Similar Papers

Loading similar papers…